Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0005203947
Wed, 22.02.2023       BRAIN Biotech AG
DE0005203947

BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment Zwingenberg (Germany), 22 February, 2023 – BRAIN Biotech AG, industrial biotechnology and enzyme expert, today announced the signing of a joint development agreement (JDA) with TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the R [ … ]
Technical analysis
To the publication
Wed, 22.02.2023       BRAIN Biotech AG
DE0005203947

BRAIN Biotech and TransCode Therapeutics join forces to develop a CRISPR-derived technology platform for cancer treatment Zwingenberg (Germany), 22 February, 2023 – BRAIN Biotech AG, industrial biotechnology and enzyme expert, today announced the signing of a joint development agreement (JDA) with TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the R [ … ]
Technical analysis
To the publication
Fri, 10.02.2023       BRAIN Biotech AG
DE0005203947

BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères Zwingenberg, Germany February 10th, 2023 BRAIN Biotech AG (“BRAIN”) today announces the contract termination with Roquette Frères for the joint development of a natural sweetener solution. BRAIN is convinced of the project’s viability and economics of a natur [ … ]
Technical analysis
To the publication
Fri, 10.02.2023       BRAIN Biotech AG
DE0005203947

BRAIN Biotech AG terminates contract for natural sweetener solution with Roquette Frères Zwingenberg, Germany February 10th, 2023 BRAIN Biotech AG (“BRAIN”) today announces the contract termination with Roquette Frères for the joint development of a natural sweetener solution. BRAIN is convinced of the project’s viability and economics of a natur [ … ]
Technical analysis
To the publication
Mon, 16.01.2023       BRAIN Biotech AG
DE0005203947

BRAIN Biotech AG reports record figures in fiscal year 2021/22 − despite challenging geopolitical environment Group sales grew by 29% Total operating performance exceeds for the first time 50 million euros Both business segments with strong growth and increasing profitability in the past fiscal year Foundations laid for ongoing future dynamic  [ … ]
Technical analysis
To the publication
Tue, 10.01.2023       BRAIN Biotech AG
DE0005203947

BRAIN Group's Akribion Genomics business will prioritize the development of therapeutic applications within its CRISPR technology platform Mode of action suited for applications in oncology Significantly increased addressable market potential Zwingenberg, Germany, 10 January 2023 − BRAIN Biotech AG today announced its intent to prioritize the dev [ … ]
Technical analysis
To the publication
Tue, 10.01.2023       BRAIN Biotech AG
DE0005203947

BRAIN Biotech AG: prioritizing development of therapeutic applications of the Akribion Genomics technology platform (genome-editing) Zwingenberg, Germany January 10th, 2023 BRAIN Biotech AG (“BRAIN”) announces that at the Supervisory Board meeting held today, the Executive Management Board of the company with the consent of the Supervisory Board  [ … ]
Technical analysis
To the publication
Mon, 09.01.2023       BRAIN Biotech AG
DE0005203947

Key Leadership Appointments at BRAIN Biotech AG, Zwingenberg Site Dr. Alexander Pelzer appointed as new Head of Research & Development, BRAIN Biotech Zwingenberg site Dr. Martin Langer takes on additional responsibility as Managing Director BioScience Operations, Zwingenberg Zwingenberg, Germany, 9 January 2023 – Biotechnology and enzyme expe [ … ]
Technical analysis
To the publication
Thu, 17.11.2022       BRAIN Biotech AG
DE0005203947

MP Beteiligungs-GmbH Increases Stake in BRAIN Biotech AG Block transaction recently successfully closed MP Beteiligungs-GmbH has increased its holding throughout 2022 Long-term supporter of the development of BRAIN Biotech AG Zwingenberg, November 17, 2022 – BRAIN Biotech AG was informed by its anchor investor MP Beteiligungs-GmbH, Kaiserslauter [ … ]
Technical analysis
To the publication
Thu, 17.11.2022       BRAIN Biotech AG
DE0005203947

MP Beteiligungs-GmbH Increases Stake in BRAIN Biotech AG Block transaction recently successfully closed MP Beteiligungs-GmbH has increased its holding throughout 2022 Long-term supporter of the development of BRAIN Biotech AG Zwingenberg, November 17, 2022 – BRAIN Biotech AG was informed by its anchor investor MP Beteiligungs-GmbH, Kaiserslauter [ … ]
Technical analysis
To the publication

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 06.10.2024, Calendar Week 40, 280th day of the year, 86 days remaining until EoY.